Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Appili Therapeutics Inc T.APLI

Alternate Symbol(s):  APLIF

Healthcare
Appili Therapeutics Inc. is a Canada-based biopharmaceutical company. The Company is advancing a diverse range of anti-infectives, including a vaccine candidate to eliminate a serious biological weapon threat, a topical antiparasitic for the treatment of a disfiguring disease, and a novel easy to use, liquid oral formulation targeting parasitic and anaerobic infections. The Company’s anti... see more

Recent & Breaking News (TSX:APLI)

Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2022

Business Wire February 14, 2022

Appili Therapeutics Expands ATI-1501 Commercial Agreement with Partner Saptalis Pharmaceuticals

Business Wire February 8, 2022

Appili Therapeutics - Press Release Correction

Business Wire December 23, 2021

Appili Therapeutics Announces Update to Funding Agreement With The Lind Partners

Business Wire December 22, 2021

Appili Therapeutics Announces Positive One Year Challenge Results from Preclinical Study Evaluating Biodefense Vaccine Candidate ATI-1701 and Change to Board of Directors

Business Wire November 19, 2021

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2022 and Change of Chief Financial Officer

Business Wire November 12, 2021

IIROC Trade Resumption - APLI

PR Newswire November 12, 2021

Appili Therapeutics Provides Update on Phase 3 PRESECO Clinical Trial Evaluating Avigan®/Reeqonus(TM)

Business Wire November 12, 2021

IIROC Trading Halt - APLI

PR Newswire November 11, 2021

Appili Therapeutics Closes $7M Overnight Offering

John Ballem  October 14, 2021

Appili Therapeutics Announces Closing of Public Offering of $7,000,220

Business Wire October 14, 2021

Appili Therapeutics (TSX:APLI) announces $7 million overnight offering

Trevor Abes  October 13, 2021

IIROC Trade Resumption - APLI

PR Newswire October 7, 2021

Appili Therapeutics Announces Pricing of Overnight Marketed Equity Offering

Business Wire October 7, 2021

IIROC Trading Halt - APLI

PR Newswire October 7, 2021

Appili Therapeutics Announces Overnight Marketed Equity Offering

Business Wire October 6, 2021

AiPharma Enters into Strategic Alliance and Stock Swap Agreement with Appili Therapeutics

PR Newswire September 29, 2021

Appili Therapeutics and AiPharma Announce Strategic Alliance and Equity Transaction

Business Wire September 29, 2021

Appili Therapeutics Announces Last Patient Enrolled in Phase 3 Trial of Oral Avigan®/Reeqonus(TM) for the Treatment of Mild-to-Moderate COVID-19

Business Wire September 23, 2021

Appili Therapeutics Announces Agreement with FUJIFILM and Funding Support for Clinical Trial Program Evaluating Avigan®/Reeqonus(TM) for COVID-19 Patients

Business Wire September 20, 2021